Last reviewed · How we verify
% 0.9 Saline solution
0.9% saline solution provides isotonic fluid replacement to maintain electrolyte balance and hydration status.
0.9% saline solution provides isotonic fluid replacement to maintain electrolyte balance and hydration status. Used for Fluid resuscitation and volume replacement in dehydration, Maintenance fluid therapy in hospitalized patients, Vehicle for intravenous medication administration.
At a glance
| Generic name | % 0.9 Saline solution |
|---|---|
| Sponsor | Kecioren Education and Training Hospital |
| Drug class | Crystalloid fluid / Electrolyte replacement solution |
| Modality | Small molecule |
| Therapeutic area | Fluid and Electrolyte Management |
| Phase | FDA-approved |
Mechanism of action
Normal saline (0.9% sodium chloride) is an isotonic crystalloid solution that matches the osmolarity of blood plasma, allowing safe intravenous administration without causing cell lysis or crenation. It is used to restore intravascular volume, maintain electrolyte homeostasis, and serve as a vehicle for medication delivery in clinical settings.
Approved indications
- Hypovolemia and dehydration
- Perioperative fluid maintenance
- Vehicle for intravenous medication administration
- Electrolyte and fluid replacement in acute care settings
Common side effects
- Hyperchloremic acidosis (with prolonged high-volume use)
- Fluid overload / pulmonary edema (in susceptible patients)
- Hypernatremia (with excessive administration)
- Phlebitis at infusion site
Key clinical trials
- Effect of Lidocaine Infusion Versus Dexmedemidine Infusion on the Neurocognitive Function of Elderly Patients Undergoing Endoscopic Retrograde Cholangiopancreatography(ERCP): a Randomized, Controlled Trial. (NA)
- PRP Injection Into the Sacroiliac Joint After Ipsilateral THA: Effects on Early Recovery and Function (SIJ-THA Randomized Trial) (NA)
- Pulse Glucocorticoid Therapy in Patients With ST-Segment Elevation Myocardial Infarction (PHASE2)
- Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC) (PHASE2, PHASE3)
- Thumb Base Osteoarthritis: Ultrasound-guided Platelet-rich Plasma Versus Placebo Injection (PHASE2)
- Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1) (PHASE1)
- Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies (PHASE1)
- Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- % 0.9 Saline solution CI brief — competitive landscape report
- % 0.9 Saline solution updates RSS · CI watch RSS
- Kecioren Education and Training Hospital portfolio CI